Trump’s 7/10 Executive Order: A Turning Point for Nephrology?
![The Accad & Koka Report](https://cdn.mises.org/styles/responsive_4_3_650w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=xcYJg8wj 650w,https://cdn.mises.org/styles/responsive_4_3_870w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=4tA-5gSL 870w,https://cdn.mises.org/styles/responsive_4_3_1090w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=HI4f-Rqa 1090w,https://cdn.mises.org/styles/responsive_4_3_1310w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=gL8uwCsq 1310w,https://cdn.mises.org/styles/responsive_4_3_1530w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=H1UV-41Y 1530w)
President Trump’s July 10, 2019, “Executive Order on Advancing American Kidney Health” may represent a major turning point in regard to how patients with chronic kidney disease are treated. We have the pleasure of having as our guest Dr. Joel Topf.
Dr. Topf is a nephrologist in private practice and a popular blogger and leader in medical social media. He is an adviser to the American Society of Nephrology and was present at the signing of the executive order. He joins Anish Koka to share his insights on the good and bad of the executive order, and on the state and future of kidney disease in the United States.